How to buy Omnicell stock - 18 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Omnicell stock

Own Omnicell stock in just a few minutes.

Omnicell, Inc is a health information services business based in the US. Omnicell shares (OMCL) are listed on the NASDAQ and all prices are listed in US Dollars. Omnicell employs 2,860 staff and has a trailing 12-month revenue of around USD0.00.

How to buy shares in Omnicell

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Omnicell. Find the stock by name or ticker symbol: OMCL. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Omnicell reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Omnicell, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Omnicell. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Omnicell share price

Use our graph to track the performance of OMCL stocks over time.

Omnicell shares at a glance

Information last updated 2021-04-16.
52-week rangeUSD$56.16 - USD$146
50-day moving average USD$133.1882
200-day moving average USD$113.3314
Wall St. target priceUSD$138.88
PE ratio 184.9595
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.74

Buy Omnicell shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Omnicell stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Omnicell under- or over-valued?

Valuing Omnicell stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Omnicell's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Omnicell's P/E ratio

Omnicell's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 185x. In other words, Omnicell shares trade at around 185x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Omnicell's PEG ratio

Omnicell's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.28. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Omnicell's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Omnicell's EBITDA

Omnicell's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$90 million.

The EBITDA is a measure of a Omnicell's overall financial performance and is widely used to measure a its profitability.

Omnicell financials

Revenue TTM USD$892.2 million
Operating margin TTM 5.83%
Gross profit TTM USD$415.9 million
Return on assets TTM 2.12%
Return on equity TTM 3.55%
Profit margin 3.61%
Book value $22.614
Market capitalisation USD$5.9 billion

TTM: trailing 12 months

Shorting Omnicell shares

There are currently 2.2 million Omnicell shares held short by investors – that's known as Omnicell's "short interest". This figure is 10.2% up from 2.0 million last month.

There are a few different ways that this level of interest in shorting Omnicell shares can be evaluated.

Omnicell's "short interest ratio" (SIR)

Omnicell's "short interest ratio" (SIR) is the quantity of Omnicell shares currently shorted divided by the average quantity of Omnicell shares traded daily (recently around 556870.63291139). Omnicell's SIR currently stands at 3.95. In other words for every 100,000 Omnicell shares traded daily on the market, roughly 3950 shares are currently held short.

However Omnicell's short interest can also be evaluated against the total number of Omnicell shares, or, against the total number of tradable Omnicell shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Omnicell's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Omnicell shares in existence, roughly 50 shares are currently held short) or 0.07% of the tradable shares (for every 100,000 tradable Omnicell shares, roughly 70 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Omnicell.

Find out more about how you can short Omnicell stock.

Omnicell share dividends

We're not expecting Omnicell to pay a dividend over the next 12 months.

Omnicell share price volatility

Over the last 12 months, Omnicell's shares have ranged in value from as little as $56.16 up to $146. A popular way to gauge a stock's volatility is its "beta".

OMCL.US volatility(beta: 1.03)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Omnicell's is 1.027. This would suggest that Omnicell's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Omnicell overview

Omnicell, Inc. , together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. In addition, the company provides automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; single dose automation solutions to fill and label for incoming prescriptions; semi-automated filling equipment for the long-term care institutional pharmacy; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site